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Recent clinical trials of non-small cell lung cancer with immune checkpoint inhibitors revealed that patients with epidermal growth factor receptor (EGFR) mutations had more unfavorable outcomes compared with those with wild-type EGFR. However, the underlying mechanism for the link between EGFR mutations and immune resistance remains unclear. We performed T cell receptor (TCR) repertoire analysis of resected lung adenocarcinoma tissues with and without EGFR mutations to investigate the characteristics of TCR repertoires. We collected a total of 39 paired (normal and tumor) lung tissue samples (20 had EGFR mutations) and conducted TCR repertoire analysis as well as whole-exome sequencing (WES) and transcriptome analysis. The TCR diversity index in EGFR-mutant tumors was significantly higher than that in EGFR-wild-type tumors (median [range] 552 [162-1,135] vs 230 ; P < .01), suggesting higher T cell clonal expansion in EGFR-wild-type tumors than in EGFRmutant tumors. In WES, EGFR-mutant tumors showed lower numbers of nonsynonymous mutations and predicted neoantigens than EGFR-wild-type tumors (P < .01, P = .03, respectively). The number of non-synonymous mutations revealed a positive correlation with the sum of frequencies of the TCRβ clonotypes of 1% or higher in tumors (r = .52, P = .04). The present study demonstrates significant differences in TCR repertoires and the number of predicted neoantigens between EGFRmutant and wild-type lung tumors. Our findings provide important information for
| INTRODUC TI ON
Lung cancer is the most common cause of cancer-related death worldwide. 1 Despite advances in treatment modalities, such as combination chemotherapy and molecular-targeted therapy, over the past few decades the survival benefit has been restricted to a subset of patients with advanced diseases. New treatment modalities are urgently needed to target and eliminate invading tumor cells.
Recently, therapeutic antibodies that block the programmed [6] [7] [8] However, the molecular mechanism underlying the lower response rates to ICI remains unclear. Thus, elucidating the mechanism that cause the differences in the clinical responses to ICI between EGFR-mutationpositive and EGFR-mutation-negative groups is important to further improve outcomes and to optimize the use of these agents in lung cancer patients.
The progress in analyzing T cell receptor (TCR) repertoires in cancer tissues made it possible to evaluate the diversity of T cell clonotypes and the extent of clonal T cell expansion, and to characterize neoantigen-specific TCR. 9 Detailed information on the tumor microenvironment may serve as a predictive marker for immunomodulatory therapies and may also be useful for development of new treatment strategies, including personalized T cell-mediated cancer immunotherapy and neoantigen vaccine therapy. [10] [11] [12] [13] [14] TCR repertoire analyses could be used to monitor the dynamics of T cell clonality and the individual tumor-reactive T cell clones in cancer patients treated with ICI. 15, 16 Profiling the immune repertoire by quantifying the TCR composition in tumor tissues enables assessment of T cell diversity and immune-related characteristics. Therefore, in the present study, we aimed to investigate the differences in immune-related conditions in EGFR-mutant/ wild-type tumors using TCR sequencing along with whole-exome sequencing (WES) analysis.
Here, we report distinct characteristics of TCR repertoire patterns in lung adenocarcinomas with and without EGFR mutations and demonstrate the association between the diversity of TCR repertoires and the numbers of non-synonymous mutations in tumors.
Our results should contribute to a better understanding of the molecular mechanism behind EGFR-mutant patients having shown an unfavorable response to ICI.
| MATERIAL S AND ME THODS

| Patients
All subjects in the present study received curative surgery between 
| Tissue samples
Tumor and adjacent normal lung tissue samples were obtained from the resected tissues. These resected tissue samples were immediately soaked in RNA later Stabilization Solution (Thermo Fisher Scientific, Waltham, MA, USA) and stored at −80°C until extraction of nucleic acids. All the samples were histologically confirmed as adenocarcinoma by pathologists.
| T cell receptor sequencing
We performed TCR sequencing as described previously.
17,18
Briefly, we synthesized complementary DNAs (cDNAs) with the common 5′-RACE adapter sequence, and amplified TCR β-chain (TCRβ) by PCR. We added Illumina index sequences with barcodes using the Nextera XT Index Kit v2 (Illumina, San Diego, CA, USA), which allows barcode tagging and pooling of multiple samples. Subsequently, the prepared library was sequenced using the MiSeq Reagent Kit v3 (600-cycle) on the MiSeq System (Illumina). We calculated the diversity index (inverse Simpson's index) to quantify the clonality of the TCRβ repertoires, as previously described. 19 understanding the molecular mechanism behind EGFR-mutant patients showing unfavorable responses to immune checkpoint inhibitors.
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| Whole-exome sequencing and data analysis
DNA and RNA were isolated using the standard procedures and the AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA, USA). Wholeexome libraries were prepared from genomic DNA using the SureSelect XT Human All Exon V6 kit (Agilent Technologies, Santa Clara, CA, USA) and analyzed as previously described. 18, 20 Human leukocyte antigen (HLA) class I genotypes were determined using the WES data of normal tissues and the OptiType algorithm. 21 Neoantigens were predicted for each non-synonymous variant by defining all 8-mer to 11-mer peptides resulting from the mutation and determining the predicted binding affinity to HLA-A, B and C of <500 nM, using NetMHCv3.4 and NetMHCpanv2.8 software.
11,22-24
| TCGA dataset analysis
We obtained the TCGA dataset from a previous publication. 25 Among these, 467 patients from the TCGA lung adenocarcinoma cohort had information of non-synonymous mutations as well as the EGFR status.
| Gene expression analysis
Gene expression quantitative PCR in tumor tissues was performed using the TaqMan gene expression assays (Thermo Fisher Scientific) on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific). mRNA expression levels of PD-1 (assay ID, Hs01550088_m1), PD-L1 (CD274; assay ID, Hs01125301_m1), CD8 (assay ID, Hs002335520_m1) and FOXP3 (assay ID, Hs01085834_m1) were evaluated and normalized to GAPDH expression (assay ID, Hs02758991_g1).
| Statistical methods
Student's t test and Fisher's exact test were performed for comparison between tumors with and without EGFR mutations. The
Mann-Whitney U test was used for comparison of the numbers of non-synonymous mutations, the TCRβ diversity index, the proportions of expanded TCRβ clonotypes, and the numbers of predicted neoantigens between tumors with and without EGFR mutations.
Multiple logistic regression models were applied to assess the association between the EGFR mutation status and the binary measures of patient characteristics, including the diversity index. Pearson correlation (r) was used to analyze the association between the proportion of TCRβ clones and non-synonymous mutations. Statistical analysis was carried out using GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA). A P-value of <.05 was considered statistically significant.
| RE SULTS
| Patients
The characteristics of patients are summarized in Table 1 . The median age of these patients was 68 years old (range: 41-85) and 25 patients (64%) were women. Nineteen patients (49%) were neversmokers, and pathological stages after curative lung resection were I for 9 patients (23%), II for 16 patients (41%) and III for 14 patients (36%). Tumors from 20 patients (51%) had EGFR mutations (an exon 19 deletion in 9 patients and an L858R mutation in 11 patients); 80% of these patients were women and 70% of them were never-smokers.
| T cell receptor repertoire analysis
To elucidate whether an EGFR mutation status affects the diversity of TCR repertoires, we performed next-generation sequencing-based 
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a total of 804 134 ± 358 995 sequence reads (average ± SD) mapped to the V, J and C segments, and identified 55 343 ± 32 756 unique CDR3 clonotypes (Table S1) Figure 1A , Table S1 ). Multivariate logistic regression analyses were undertaken to examine whether the correlation between the diversity index and the EGFR status would be influenced by differences in patient characteristics such as age, sex, smoking and pathological stage. We found that the TCRβ diversity index (High: greater than median value) and smoking status (non-smoker) were independently associated with EGFR mutation status (P = .04 and .02, respectively; Table 2 ).To further examine differences in the proportions of the expanded T cell clones in the 2 groups with and without EGFR mutations, we compared the sum of frequencies of the TCRβ clonotypes of 1% or higher in the 2 groups ( Figure 1B , Table S1 ). Figure 1C) . The results showed the same tendencies when we used the sum of frequencies of the TCRβ clonotypes of .5% and 2% as cut-off values (P = .02, P < .01, respectively; Figure S1) 
| Comparison of the numbers of somatic nonsynonymous mutations/predicted neoantigens between epidermal growth factor receptormutant and wild-type tumors
To assess a relationship between the EGFR status and the numbers of somatic non-synonymous mutations, we compared the numbers in tumors with and without EGFR mutations. WES analysis was performed for 16 randomly selected cases (Del19/L858R/wild type were 5/4/7, respectively) from the 39 lung adenocarcinomas. We identified a total of 906 somatic non-synonymous mutations per individual patients; Table S2 Table   S2 ). Subsequently, we compared the number of candidate peptides in the 2 groups with and without EGFR mutations and found that tumors with EGFR mutations had significantly lower numbers of predicted neoantigens than those without EGFR mutations (median: 57 vs. 157 [47-247]; P = .03; Figure 1E ).
| Correlation between the proportion of expanded T cell receptor β clones and the number of non-synonymous mutations
To analyze the relationship between the clonal expansions of T cells in tumor microenvironment and the numbers of non-synonymous mutations, we compared the sum of frequencies of the TCRβ clonotypes of 1% or higher with the number of non-synonymous mutations in the 2 groups with and without EGFR mutations (Figure 2 ).
The numbers of non-synonymous mutations were significantly correlated with the clonal T cell expansions in the tumor tissues (r = .52, P = .04).
| Immune-related gene expression analysis
Because PD-1/PD-L1 expression is important to immune responses in tumors, including the efficacy to ICI, we assessed PD-1/PD-L1 expression levels in tumors with and without EGFR mutations. We measured mRNA expression levels of PD-1 and PD-L1 in 39 lung adenocarcinomas and compared the expression levels between the 2 groups. We observed no significant differences in PD-1 and PD-L1 mRNA expression levels between the EGFR-mutant and wild-type groups (P = .09, P = .25, respectively). We also observed no significant differences in the CD8/FOXP3 ratio between the 2 groups (P = .38). However, we found the tendency of a higher PD-1/CD8 
| D ISCUSS I ON
The underlying biology for lower clinical response rates of ICI in lung adenocarcinomas having EGFR mutations is not well understood.
Hence, identification of predictive biomarkers for responses to ICI is critical for lung cancer patients with EGFR mutations. We analyzed immune-related microenvironment in tumors with and without EGFR mutations using TCRβ repertoire analysis and WES. Our study is the first to characterize distinct TCR repertoire patterns between 2 groups of lung adenocarcinoma with and without EGFR mutations;
we also clarified the association between the diversity of TCR repertoires and the mutational load in tumors. Our findings may evoke further understanding of the molecular mechanism through which EGFR-mutant patients show poor clinical responses to ICI.
In this study, we demonstrated that the sum of frequencies of the TCRβ clonotypes of 1% or higher in tumors with wild-type EGFR were significantly higher than those in tumors with EGFR mutations In addition, patients' characteristic may affect the efficacy of ICI.
EGFR mutations are found in female patients with no history of tobacco smoking. 31, 32 Our study population also showed more women than men in the EGFR-mutated group. Interestingly, the pooled analysis showed that a higher benefit of ICI treatment was observed in men than women, regardless of histological type. 33 Furthermore, several studies report that tobacco smoking leads to a higher mutation burden in human cancers. 27, 34, 35 PD-L1 expression levels may affect the clinical benefit of ICI.
In the combined analysis of 15 reported studies, EGFR-mutated tumors showed low PD-L1 expression in tumors 30 and recent studies demonstrated that PD-L1 expression levels were associated with EGFR mutation status. 36, 37 However, in this study, PD-1/PD-L1 expression levels were not significantly different between the 2 groups with and without EGFR mutations. Accumulated data now indicates that the PD-L1 status alone is not a useful biomarker for the prediction of the efficacy of ICI. [38] [39] [40] In conclusion, the present study offers novel evidence that lung adenocarcinoma with EGFR mutations have a higher TCRβ diversity index and a lower number of neoantigens compared with tumors without EGFR mutations, and could explain impaired responses to ICI. Furthermore, TCR repertoire analysis might provide useful information for identification of good responders for immunotherapy in EGFR-mutant NSCLC.
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